Samantha Pazienza

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva et al. · The Lancet Oncology · 2021 · 102 citations

Medicine, Hematology, Pharmacology +11

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva et al. · Blood · 2021 · 75 citations · Full text

Pharmacy, Pharmacotherapy, Translational Medicine +1

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Christine E. Ryan, Benjamin L. Lampson, Svitlana Tyekucheva et al. · Blood · 2022 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +6

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva et al. · Blood · 2020 · 19 citations

Medicine, Hematology, Pharmacology +11

A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.

Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva et al. · Journal of Clinical Oncology · 2020 · 12 citations

Medicine, Oncology, Pharmacotherapy +9